Archives: 12/2006

StarLux Laser Hair Removal Comes Home
Palomar’s StarLux laser hair removal system has been available in salons for about ten years. But now, the FDA has approved a version that consumers can take home with them.

Pulsed Light hair removal works by emitting pulses of intense light into the hair follicles. The light is absorbed by the pigment in the follicles and converted to heat. The heat then loosens the hair and disables the cells responsible for growing new hair.
“This system gives a rapid hair reduction with less discomfort and less treatment time than pre-existing products and at a cost that is more affordable to the doctor and the patient.”

They say they’ll be marketing the home version to women, but it’s, ah, strong enough for a man (warning: not safe for lunch).
More from BusinessWeek, who called Palomar a “top 10 growth company”…

9854alg1 Learning Nanomaterials from DiatomsPictured on the right is diatom Thalassiosira pseudonana, a microscopic algae known for its intricately constructed cell walls. Scientists from Georgia Tech are trying to learn how these simple, well-described organisms, build such walls. One day, when we are smarter than diatoms, we might be able to imitate these organisms in developing novel nanomaterials:

“Diatoms are nature’s most gifted nanotechnologists,” said Nils Kröger, an assistant professor in Georgia Tech’s School of Chemistry and Biochemistry and the School of Materials Science and Engineering. “We want to learn how diatom cell walls are produced because human technology can’t make something that intricate by self-assembly processes and under ambient conditions…”
The pores allow diatoms to be lightweight, but their cell wall gives them a strong mechanical structure. The strength of the cell wall comes from amorphous silica, or silicon dioxide (SiO2)–virtually the same material as glass.
Diatom cell walls show an enormous diversity in form, most of them amazingly beautiful and ornate, depending on specific biomolecules produced by the diatom, Kröger explained. Previous research has shown that uniquely modified proteins called silaffins and extremely long polyamine chains play a role in the structural design of the cell wall. Kröger hypothesizes that the structure of the diatom silica critically depends on the type of silaffin present within the diatoms’ silica-producing organic matrix. Therefore, he expects that changing the “silaffin equipment” of a diatom cell should result in novel silica nanostructures.
Kröger and collaborator Nicole Poulsen, a postdoctoral researcher in the School of Chemistry and Biochemistry, have developed a technique to genetically engineer diatoms. The process allows insertion of mutated or foreign genes into the genome of the diatom Thalassiosira pseudonana. Kröger believes this technique will enable the creation of diatoms with novel silica structures. He will describe the technique in an invited presentation on Dec. 12 at the fall meeting of the American Geophysical Union.
Genetic manipulation of diatoms will increase the understanding of their cellular biochemistry and potentially enable the use of these organisms for the production of commercially valuable compounds and materials, Kröger said. But inserting a gene through the strong silica cell wall is difficult. The wall must be penetrated, but not broken, and the foreign gene must be accepted into the diatom’s genome, he explained.
To insert the genes, such as those that encode different silaffins, through the diatom cell wall, Kröger and Poulsen use a technique called microparticle bombardment. DNA-coated tungsten particles are “shot” on the diatoms under high heliumpressure, thus enabling them to penetrate the strong diatom cell wall. The diatom incorporates the introduced DNA into its genome, and selection of the transfected cells is achieved using the antibiotic nourseothricin. When new genes are introduced with the technique developed by Kröger and Poulsen, they can be expressed constantly or be turned on and off when necessary.

Link

At the ongoing annual meeting of the American Society for Cell Biology in San Diego, a team of investigators from Carnegie Mellon University and University of Pittsburgh presented research on how to direct differentiation of stem cells and, at the same time, to position them in specific tissue-like patterns. The big idea for the future is to build replacement organs, of course.

The custom-built ink-jet printer, developed at Carnegie Mellon’s Robotics Institute, can deposit and immobilize growth factors in virtually any design, pattern or concentration, laying down patterns on native extracellular matrix-coated slides (such as fibrin). These slides are then placed in culture dishes and topped with muscle-derived stem cells (MDSCs). Based on pattern, dose or factor printed by the ink-jet, the MDSCs can be directed to differentiate down various cell-fate differentiation pathways (e.g. bone- or muscle-like).
“Previously, researchers have been limited to directing stem cells to differentiate toward multiple lineages in separate culture vessels. This is not how the body works: the body is one vessel in which multiple tissues are patterned and formed. The ink-jet printing technology allows us to precisely engineer multiple unique microenvironments by patterning bio-inks that could promote differentiation towards multiple lineages simultaneously,” explained Phil Campbell, research professor at Carnegie Mellon’s Institute for Complex Engineered Systems.
“Controlling what types of cells differentiate from stem cells and gaining spatial control of stem cell differentiation are important capabilities if researchers are to engineer replacement tissues that might be used in treating disease, trauma or genetic abnormalities,” said Lee Weiss, research professor at Carnegie Mellon’s Robotics Institute.
“This system provides an unprecedented means to engineer replacement tissues derived from muscle stem cells,” said Johnny Huard, professor of orthopedic surgery at the University of Pittsburgh School of Medicine and director of the Stem Cell Research Center at Children’s Hospital of UPMC. Huard has long-standing research findings that show how muscle-derived stem cells (MDSCs) from mice can repair muscle in a model for Duchenne Muscular Dystrophy, improve cardiac function following heart failure, and heal large bone and articular cartilage defects.
Weiss and Campbell, along with graduate student Eric Miller, previously demonstrated the use of ink-jet printing to pattern growth factor “bio-inks” to control cell fates. For their current research, they teamed with Phillippi, Huard and biologists of the Stem Cell Research Center at Children’s Hospital to gain experience in using growth factors to control differentiation in populations of MDSCs from mice.
The Carnegie Mellon scientists used computer-vision feedback to calibrate how bio-inks were jetted onto their targets with micrometer precision to facilitate subsequent image analysis. They stained the MDSC cultures for cell markers to confirm that muscle and bone-like lineages “lined-up” in register with engineered bio-ink patterns that were initially printed onto the slides with the ink-jet printer.
“Our findings showed that we successfully engineered MDSCs to become subpopulations of muscle or bone-like cells that were patterned using our bio-ink-jet system,” said Phillippi. “This experiment represents a key first step in demonstrating the potential of this technology to learn more about not only the basic biology of how multiple cell types are patterned in the body during development, repair and regeneration, but also for translating adult stem cells into real therapies for patients in the future.”
The team, along with Alan Waggoner, professor of biological sciences and director of Carnegie Mellon’s Molecular Biosensor Imaging Center, is now developing novel biosensors and fluorescent-based techniques to visualize stem cell differentiation in response to the bio-ink patterns.
Because the ink-jet system employs such precision, it could be used one day to co-culture multiple MDSC lineages – including bone, muscle and other cell types – in complex, patterned configurations that could be incorporated directly into specific areas of the body in need of repair of multiple tissue types, according to the investigators.
The Pittsburgh team envisions the ink-jet technology as potentially useful for engineering stem cell-based therapies for repairing defects where multiple tissues are involved, such as joints where bone, tendon, cartilage and muscle interface.

Link
Flashback: Inkjet Printing of Human Tissues

98633tms FDA to Consider Transcranial Magnetic Stimulation System
Remember transcranial magnetic stimulation (TMS), a noninvasive procedure in which electrical activity of the brain is “buzzed” by an alternating magnetic field, through magnetic induction? We’ve followed TMS for quite some time now, for its purported usefulness in depression, schizophrenia, migranes, and vision — not to mention its potential to induce temporary “Rain Man” – like savant states.
98633tms2 FDA to Consider Transcranial Magnetic Stimulation SystemAccording to the Associated Press, the FDA is planning to consider for approval a TMS device, developed for the treatment of major depression, called Neurostar System by Neuronetics.
To learn more about the Neurostar System, go to its product page
Neuronetics’ technology page
Flashbacks: Medgadget’s transcranial magnetic stimulation archives…

Scientists from Cornell are reporting in the latest issue of Annals of Neurology that they have identified 23 protein biomarkers of Alzheimer’s. The bad news? These biomarkers are in the cerebrospinal fluid, and not in blood.

“Our study is the first to use sophisticated proteomic methods to hone in on a group of cerebrospinal fluid biomarkers that are specific to autopsy-proven Alzheimer’s disease. Those postmortem tests confirmed that the panel is over 90 percent sensitive in identifying people with Alzheimer’s disease,” says Kelvin Lee, the Samuel C. and Nancy M. Fleming Professor of Molecular and Cell Biology and associate professor of chemical and biomolecular engineering at Cornell…
The Cornell study combined cutting edge “proteomics” technology, detailed image analysis, and complex computational and statistical analyses to simultaneously compare 2,000 cerebrospinal fluid proteins from 34 patients with autopsy-proven Alzheimer’s disease to those of 34 age-matched controls without the disease.
“Just as the human genome reflects the array of genes a person possesses, the ‘proteome’ is the vast collection of proteins expressed by those genes,” said Lee. “Essentially we used high-tech methods to contrast the proteomes of Alzheimer’s patients against those of a control cohort that included people with other forms of dementia as well as healthy individuals, looking for key differences between the two groups.”
This effort yielded intriguing results: 23 proteins that individually might not point to Alzheimer’s but together formed an identifying pattern or “fingerprint” specific to the illness.
“Although it need not have turned out that way, several of the 23 markers that emerged from this analysis proved to be proteins with known links to the pathological mechanisms of Alzheimer’s disease,” said Relkin. [Norman Relkin M.D. is an associate professor of clinical neurology and neuroscience at Weill Cornell --ed.]
For example, some of the biomarkers are associated with proteins that clog the brains of Alzheimer’s patients. Others molecules were linked to inflammation, also a part of Alzheimer’s brain pathology. Still other proteins in the panel were linked to synaptic dysfunction — the breakdown of communication between brain cells that occurs as Alzheimer’s disease progresses.
“A subsequent validation group of 10 patients with suspected Alzheimer’s and 18 healthy and demented control subjects turned up similar results,” said Relkin. “Based on their clinical symptoms, we found the new screen to have 93 percent sensitivity to probable cases of Alzheimer’s and a 90 percent accuracy in avoiding false diagnoses.”
Despite their excitement over the new findings, the researchers stress that the results still need to be replicated in much larger populations.

The press release
(hat tip: Drudge Report)

87678thom1 Thomson Clinical Xpert
Thomson Healthcare, the company that produces the Physicians’ Desk Reference® (PDR), has introduced a PDA-based tool for clinicians, dubbed Thomson Clinical Xpert.
We just downloaded this free package today, hence no comments on its usability in a clinical environment. The features are impressive, so you might as well try it out together with us:

Thomson Clinical Xpert features premium content from Thomson Micromedex, one of the most respected providers of evidence-based clinical information. Experienced physicians, pharmacists, toxicologists, nurses and other healthcare professionals at Micromedex develop and review Thomson Clinical Xpert content, giving clinicians information of unparalleled authority and accuracy, including:

  • A searchable database of more than 4,000 drugs with comprehensive indications, dosage and interactions information
  • Details on more than 400 laboratory tests and their interpretations
  • Toxicology reports on more than 200 of the most common poisons and drug overdoses
  • A comprehensive disease database that offers differential diagnoses, therapeutics and evidence-based recommendation ratings
  • Detailed information about alternative medicines
  • Thomson Clinical Xpert also features drug interaction tools, convenient medical calculators and “Xpert Alerts”–electronic advisories regarding key drug changes or treatment studies delivered directly to users PDA, desktop or PDR.net account.

    Press release
    Product page

    986798fdd Novel Anesthetic Discovered in Sea SnailDr. Jenny Ekberg and colleagues at the University of Queensland have discovered that a toxin from marine snail Conus marmoreus has interesting analgesic properties, similar to local anesthetics but without any motor blockade.
    From the interview Dr. Ekberg gave to the press office of University of Queensland:

    “The patient experiences severe pain because their nerve cells that are responsible for pain transmission are overactive,” she said.
    “This is primarily due to abnormal activity of voltage-gated sodium channels in the nerve cells.
    “Conventional drugs, such as local anaesthetics, block all types of sodium channels, causing severe side-effects.
    “Our toxin only blocks a specific channel — the first time a toxin like this has been shown to work– therefore providing pain relief without severe side-effects.”

    More
    Full article at PNAS

    award lr The 2006 Medical Weblog Awards

    Welcome to the third annual Medical Weblog Awards! These awards are designed to honor the very best in the medical blogosphere, and to highlight the diverse world of medical blogs.
    The categories for this year’s awards will be:
    – Best Medical Weblog
    – Best New Medical Weblog (established in 2006)
    – Best Literary Medical Weblog
    – Best Clinical Sciences Weblog
    – Best Health Policies/Ethics Weblog
    – Best Medical Technologies/Informatics Weblog
    – Best Patient’s Blog (a new category this year)
    Nominations are now accepted in the comment section of this post. When nominating, please indicate blog’s name and URL. A blog can participate in more than one category, so please indicate which one(s).
    The following timeline will be observed:
    – Nominations will be accepted until Sunday, December 31, 2006.
    – Polls will be open from Wednesday, January 3, 2007 and will close at midnight on Sunday, January 14, 2007 (PST).
    – Awards will be announced on Friday, January 19, 2007.
    655522wff The 2006 Medical Weblog Awards
    This year’s awards are being sponsored by Thinklabs Medical and Medgadget. Thinklabs will be giving a complete Thinklabs Stethoscope Recording Package to the winner of the Best Medical Weblog. The prize includes a Thinklabs ds32a Electronic Stethoscope and a 2GB Apple iPod Nano with a Micromemo recording accessory.
    Winners in other categories, in addition to bragging rights, will be awarded by Medgadget with the latest edition of The Merck Manual of Diagnosis and Therapy. Offers are accepted from individuals and companies to provide additional gifts for the winners (please write to medgadget-at-medgadget-dot–com).
    Medgadget.com, as well as the individual blogs of our editors, are not eligible to participate in the awards.
    This year, we are introducing a new voting system. Please meet the judges: Medgadget editorial staff is joined by Sumer from Sumer’s Radiology Site, Josh from Kidney Notes, Enoch from Tech Medicine, Orac from Respectful Insolence, Steven from docinthemachine, Bard from A Chance to Cut is a Chance to Cure, Amy from Diabetes Mine and Allen from GruntDoc. Judges will conduct a review of each blog submitted and will vote to sort out those blogs that don’t belong to a particular category, or simply splogs (spam blogs.) Furthermore, judges will vote for blogs. Your votes and judges’ votes are counted as 50% to 50%. Such a voting system was held at a recent TV show Dancing with the Stars, and details on how the counting was done can be found here.
    Voting for the awards will be open to all, but you will only be able to vote once. (No hacking or cookie manipulation will be tolerated — only one vote for each category from a particular IP address.)
    All final decisions will be made by our editors.
    Good luck to all!
    UPDATE: The 2006 Medical Weblog Awards Nominees
    UPDATE: Vote now!

    9876s4aqq Generation NeXt UltrasoundsAt EUROECHO 10, a recently held cardiology congress in Prague, Siemens AG demonstrated its new line of echo machines called “Generation NeXt.” Acuson X300 and Acuson Antares are components of a new line being promoted.
    Here’s how Siemens describes its “Generation NeXt”:

    The ultra-sound systems Acuson X300 and Acuson Antares, both shown for the first time at a cardiology congress, provide outstanding performance through advanced offline and online applications such as the syngo Arterial Health Package and syngo Mitral Valve Assessment…
    With an operator-friendly console that helps to reduce arm and hand movement, and its small, lightweight transducers, the X300 takes the pain and pressure out of routine scanning. A flat panel display, height adjustable control panel and its light weight design enables a comfort-able scanning position for the user, even in tight exam spaces such as the patient’s bedside. The system’s TGO (tissue grayscale optimization) technology delivers consis-tent image quality, while advanced Hanafy lens transducers enable improved image uniformity when scanning technically difficult-to-image patients.
    With the introduction of shared service capabilities to the Acuson Antares ultrasound system, the benefits of a revolutionary design as well as the outstanding image quality and versatility will now also be available to the cardiologist. The Antares system, premium edition, 5.0 release is equipped with a high-resolution 19-inch flat panel display mounted on an articulating arm for optimal viewing position. Other ergonomic design features include the natural and extended reach zone concept that places controls and peripheral devices so they are easily accessible allowing for more comfortable patient exams, and improved examination and departmental workflow…
    The syngo Arterial Health Package allows the evaluation of cardiac risk factors and quantification of cardiovascular age with auto-mated intima-media thickness measurements while the syngo Mitral Valve Assessment application provides for a rapid 3D/4D evaluation of mitral valve morphology and pa-thology for diagnosis and planning of surgical procedures. Both of these applications will also be available “online” on the Acuson Sequoia ultrasound system’s 12.0 release.

    Press release
    ACUSON X300 system product page
    ACUSON Antares product page